Financhill
Sell
28

TRIB Quote, Financials, Valuation and Earnings

Last price:
$0.71
Seasonality move :
0.07%
Day range:
$0.63 - $0.67
52-week range:
$0.48 - $3.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.13x
P/B ratio:
--
Volume:
64.3K
Avg. volume:
66.9K
1-year change:
-61.1%
Market cap:
$11.8M
Revenue:
$61.6M
EPS (TTM):
-$2.28

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TRIB
Trinity Biotech PLC
$16M -$0.28 8.81% -25.13% --
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
AKTX
Akari Therapeutics PLC
-- -- -- -- --
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.94
CLLS
Cellectis SA
$13.8M -- 36.24% -100% $5.60
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.99% $18.41
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TRIB
Trinity Biotech PLC
$0.63 -- $11.8M -- $0.00 0% 0.13x
ADAP
Adaptimmune Therapeutics PLC
$0.27 $1.58 $71.9M -- $0.00 0% 0.39x
AKTX
Akari Therapeutics PLC
$1.30 -- $41.8M -- $0.00 0% --
BDRX
Biodexa Pharmaceuticals PLC
$1.05 $17.94 $2.7M -- $0.00 0% 1.09x
CLLS
Cellectis SA
$1.41 $5.60 $141.4M -- $0.00 0% 2.89x
DBVT
DBV Technologies SA
$9.35 $18.41 $255.7M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TRIB
Trinity Biotech PLC
147.47% -1.250 785.94% 0.87x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.631 50.03% 1.57x
AKTX
Akari Therapeutics PLC
-- -2.630 -- --
BDRX
Biodexa Pharmaceuticals PLC
-- 2.357 -- 1.20x
CLLS
Cellectis SA
30.41% 0.907 56.64% 1.64x
DBVT
DBV Technologies SA
-- -3.919 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TRIB
Trinity Biotech PLC
$5.3M -$2.2M -45.03% -- -11.29% -$6.3M
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
AKTX
Akari Therapeutics PLC
-- -$3.5M -- -- -- -$2.2M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M

Trinity Biotech PLC vs. Competitors

  • Which has Higher Returns TRIB or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -653.18%. Trinity Biotech PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About TRIB or ADAP?

    Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 481.43%. Given that Trinity Biotech PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Trinity Biotech PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRIB
    Trinity Biotech PLC
    0 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is TRIB or ADAP More Risky?

    Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.

  • Which is a Better Dividend Stock TRIB or ADAP?

    Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TRIB or ADAP?

    Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Trinity Biotech PLC's net income of -$4.8M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus 0.39x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M
    ADAP
    Adaptimmune Therapeutics PLC
    0.39x -- $7.3M -$47.6M
  • Which has Higher Returns TRIB or AKTX?

    Akari Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
    AKTX
    Akari Therapeutics PLC
    -- -- --
  • What do Analysts Say About TRIB or AKTX?

    Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6053.85%. Given that Akari Therapeutics PLC has higher upside potential than Trinity Biotech PLC, analysts believe Akari Therapeutics PLC is more attractive than Trinity Biotech PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRIB
    Trinity Biotech PLC
    0 0 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is TRIB or AKTX More Risky?

    Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.306%.

  • Which is a Better Dividend Stock TRIB or AKTX?

    Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TRIB or AKTX?

    Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$3.7M
  • Which has Higher Returns TRIB or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About TRIB or BDRX?

    Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1608.94%. Given that Trinity Biotech PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Trinity Biotech PLC is more attractive than Biodexa Pharmaceuticals PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRIB
    Trinity Biotech PLC
    0 0 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is TRIB or BDRX More Risky?

    Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.

  • Which is a Better Dividend Stock TRIB or BDRX?

    Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TRIB or BDRX?

    Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus 1.09x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M
    BDRX
    Biodexa Pharmaceuticals PLC
    1.09x -- -- --
  • Which has Higher Returns TRIB or CLLS?

    Cellectis SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -170.14%. Trinity Biotech PLC's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
  • What do Analysts Say About TRIB or CLLS?

    Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 297.16%. Given that Trinity Biotech PLC has higher upside potential than Cellectis SA, analysts believe Trinity Biotech PLC is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRIB
    Trinity Biotech PLC
    0 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is TRIB or CLLS More Risky?

    Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock TRIB or CLLS?

    Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TRIB or CLLS?

    Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Cellectis SA quarterly revenues of $10.7M. Trinity Biotech PLC's net income of -$4.8M is higher than Cellectis SA's net income of -$18.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus 2.89x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M
    CLLS
    Cellectis SA
    2.89x -- $10.7M -$18.1M
  • Which has Higher Returns TRIB or DBVT?

    DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About TRIB or DBVT?

    Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand DBV Technologies SA has an analysts' consensus of $18.41 which suggests that it could grow by 96.89%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRIB
    Trinity Biotech PLC
    0 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is TRIB or DBVT More Risky?

    Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock TRIB or DBVT?

    Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TRIB or DBVT?

    Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
10
EXOD alert for May 29

Exodus Movement [EXOD] is up 15.65% over the past day.

Buy
80
SBET alert for May 29

SharpLink Gaming [SBET] is up 144.58% over the past day.

Buy
100
BOX alert for May 29

Box [BOX] is up 0.46% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock